

1 **Co-detection of respiratory pathogens in patients hospitalized with Coronavirus**
2 **viral disease-2019 pneumonia**

3 María Luisa Blasco^a, Javier Buesa^{b,c}, Javier Colomina^b, María José Forner^{d,e}, María José
4 Galindo^{d,e}, Jorge Navarro^f, José Noceda^g, Josep Redón^{d,e}, Jaime Signes-Costa^h, and
5 David Navarro^{b,c#}

6 ¹*Medical Intensive Care Unit, Clinic University Hospital, INCLIVA Health Research*
7 *Institute, Valencia, Spain.*

8 ²*Microbiology Service, Clinic University Hospital, INCLIVA Health Research Institute,*
9 *Valencia, Spain.*

10 ³*Department of Microbiology, School of Medicine, University of Valencia, Valencia,*
11 *Spain.*

12 ⁴*Internal Medicine Department, Clinic University Hospital, INCLIVA Health Research*
13 *Institute, Valencia, Spain.*

14 ⁵*Department of Medicine, School of Medicine, University of Valencia, Valencia, Spain.*

15 ⁶*Medical Directory, Clinic University Hospital, INCLIVA Health Research Institute,*
16 *Valencia, Spain.*

17 ⁷*Emergency Medical Service, Clinic University Hospital, Valencia, Spain.*

18 ⁸*Pneumology Service, Clinic University Hospital, INCLIVA Health Research Institute,*
19 *Valencia, Spain.*

20

21 **Running title:** Co-infection with respiratory pathogens in Covid-19.

22 **#Correspondence:** David Navarro, Microbiology Service, Hospital Clínico
23 Universitario, Instituto de Investigación INCLIVA, Valencia, and Department of
24 Microbiology, University of Valencia, Valencia, Spain. Av. Blasco Ibáñez 17, 46010

25 Valencia, Spain. Phone: 34(96)1973500; Fax: 34(96)3864173; E-mail:
26 david.navarro@uv.es.

27

28 **ABSTRACT**

29 There is scarce information on the frequency of co-detection of respiratory pathogens
30 (RP) in patients with Covid-19. Documentation of coinfections in Covid-19 pneumonia
31 patients may be relevant for appropriate clinical and therapeutic management of
32 patients. Between March 4th and March 28th, 2020, a total of 183 adult patients testing
33 positive by SARS CoV-2 RT-PCR on respiratory specimens were hospitalized with
34 interstitial pneumonia at our center, of whom 103 were tested for other RP by a
35 multiplexed PCR assay. Three patients had a positive result for either one (n=2;
36 Coronavirus HKU1 or Mycoplasma pneumoniae) or two targets (n=1; Influenza virus A
37 (H3) and Respiratory syncytial virus B). Twenty-three patients testing negative by
38 SARS CoV-2 RT-PCR and presentig with clinical, laboratory findings and imaging
39 compatibe with Covid-19 pneumonia underwent RP screening. Of these, 6 (26%) had a
40 positive result for a single RP. Our data indicate that despite the apparent rarity of
41 coinfections in patients with Covid-19 pneumonia, routine testing for RP should be
42 advised, since agents for which specific therapy can be prescribed may be detected.

43

44

45

46

47

48

49 Clinical, laboratory and imaging characteristics of Coronavirus disease 2019 (Covid-19)
50 and risk factors associated with poor outcomes have been reported in various studies (1-
51 5). Information on whether other respiratory pathogens (RP) were co-detected in these
52 patients was not provided, despite the fact that coinfection with RP has been reported to
53 occur in this clinical setting (6-9). Documentation of coinfections in Covid-19
54 pneumonia patients may be relevant not only for appropriate clinical and therapeutic
55 management of patients, but also to precisely characterize disease features and delineate
56 risk factors potentially impacting on clinical outcomes. Here, we report on our
57 experience on this topic, gathered between March 4th and March 28th, 2020, at the
58 Clinic University Hospital of Valencia, a tertiary teaching hospital with 586 beds which
59 serves Clínico-Malvarrosa Health Department (attending 368.000 inhabitants in the
60 northeast of the city). The study was approved by the Ethical Committee of University
61 Clinic Hospital, INCLIVA, Valencia. Informed consent was not requested as laboratory
62 analyses reported herein were conducted routinely in our patients following local
63 guidelines.

64 A total of 183 adult patients testing positive by SARS CoV-2 RT-PCR on respiratory
65 specimens were hospitalized with interstitial pneumonia, of whom 103 (64 males/39
66 females; median age, 64 years; range, 19-100 years) were tested for other RP by a
67 multiplexed PCR assay (10) (Table 1). Three patients (2.9%) had positive results for
68 either one (n=2; Coronavirus HKU1 or *Mycoplasma pneumoniae*) or two targets (n=1;
69 Influenza virus A (H3) and Respiratory syncytial virus B). Twenty-three patients (14
70 males/9 females; median age, 54 years; range, 31-79 years) testing negative by SARS
71 CoV-2 RT-PCR in a single respiratory specimen, presentig with clinical, laboratory

72 findings and imaging compatible with Covid-19 pneumonia (1-5) underwent RP
73 screening. Of these, 6 (26%) had a positive result for a single RP.

74 Coinfection with RP in adult patients with respiratory tract infections occurs commonly
75 (11,12). In line with this, coinfection with RP was observed in 2 out of 12 patients
76 (25%) presenting with upper or lower respiratory tract infections and no clinical
77 suspicion of Covid-19 and testing positive for RP within the study period. The rate of
78 co-detection of RP in the same time period of the preceding year was rather comparable
79 (6 out of 18 patients testing positive for RP; 35%). Nevertheless, patients with Covid-19
80 pneumonia were found to be infrequently coinfecting with other RP; this phenomenon
81 could have been underestimated, since 26% of patients fulfilling criteria of this clinical
82 entity (1-5) and testing negative by SARS CoV-2 RT-PCR, had RP detected in
83 respiratory specimens. In this sense, false negative SARS CoV-2 PCR results in upper
84 respiratory tract specimens occurs (13). The possibility of a viral interference
85 phenomenon similar to that described for influenza virus A (sub)types should also be
86 considered (14). Despite the apparent rarity of coinfections in patients with Covid-19
87 pneumonia, routine testing for RP should be advised, since agents for which specific
88 therapy can be prescribed (i.e. *Mycoplasma pneumoniae*, Influenza virus A, or
89 Respiratory syncytial virus) may be detected. This approach may have a beneficial
90 impact on patient survival.

91 **Funding**

92 The current work received no public or private funding.

93 **Conflicts of Interest**

94 The authors declare no conflicts of interest

95 **Acknowledgements**

96 We are grateful to all personnel who work at Clinic University Hospital for their
97 dedicated and tireless effort in the fight against Covid-19.

98 REFERENCES

- 99 1. **Wang Z, Yang B, Li Q, Wen L, Zhang R.** 2020. Clinical Features of 69 Cases with
100 Coronavirus Disease 2019 in Wuhan, China. *Clin Infect Dis*; Mar 16. pii: ciaa272. doi:
101 10.1093/cid/ciaa272. [Epub ahead of print].
- 102 2. **Mo P, Xing Y, Xiao Y, Deng L, Zhao Q, Wang H, Xiong Y, Cheng Z, Gao S,**
103 **Liang K, Luo M, Chen T, Song S, Ma Z, Chen X, Zheng R, Cao Q, Wang F, Zhang**
104 **Y.** 2020. Clinical characteristics of refractory COVID-19 pneumonia in Wuhan, China.
105 *Clin Infect Dis*; Mar 16. pii: ciaa270. doi: 10.1093/cid/ciaa270. [Epub ahead of print].
- 106 3. **Wang D, Hu B, Hu C, Zhu F, Liu X, Zhang J, Wang B, Xiang H, Cheng Z,**
107 **Xiong Y, Zhao Y, Li Y, Wang X, Peng Z..** 2020. Clinical Characteristics of 138
108 Hospitalized Patients With 2019 Novel Coronavirus-Infected Pneumonia in Wuhan,
109 China. *JAMA*; Feb 7. doi: 10.1001/jama.2020.1585. [Epub ahead of print].
- 110 4. **Zhou F, Yu T, Du R, Fan G, Liu Y, Liu Z, Xiang J, Wang Y, Song B, Gu X,**
111 **Guan L, Wei Y, Li H, Wu X, Xu J, Tu S, Zhang Y, Chen H, Cao B.** 2020. Clinical
112 course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan,
113 China: a retrospective cohort study. *Lancet*; Mar 28;395(10229):1054-1062. doi:
114 10.1016/S0140-6736(20)30566-3. Epub 2020 Mar 11.
- 115 5. **Guan WJ, Ni ZY, Hu Y, Liang WH, Ou CQ, He JX, Liu L, Shan H, Lei CL, Hui**
116 **DSC, Du B, Li LJ, Zeng G, Yuen KY, Chen RC, Tang CL, Wang T, Chen PY,**
117 **Xiang J, Li SY, Wang JL, Liang ZJ, Peng YX, Wei L, Liu Y, Hu YH, Peng P,**
118 **Wang JM, Liu JY, Chen Z, Li G, Zheng ZJ, Qiu SQ, Luo J, Ye CJ, Zhu SY, Zhong**

- 119 **NS.** 2020. Clinical Characteristics of Coronavirus Disease 2019 in China. *N Engl J*
120 *Med*; Feb 28. doi: 10.1056/NEJMoa2002032. [Epub ahead of print].
- 121 6. **Wu X, Cai Y, Huang X, u X, Zhao L, Wang F, Li Q, Gu S, Xu T, Li Y, Lu B,**
122 **Zhan Q.** 2020. Co-infection with SARS-CoV-2 and influenza A virus in patient with
123 pneumonia. Co-infection with SARS-CoV-2 and Influenza A Virus in Patient with
124 Pneumonia, China. *Emerg Infect Dis*; Mar 11; 26(6). doi: 10.3201/eid2606.200299.
- 125 7. **Lin D, Liu L, Zhang M, Hu Y, Yang Q, Guo J, Guo Y, Dai Y, Xu Y, Cai Y, Chen**
126 **X, Zhang Z, Huang K.** 2020. Co-infections of SARS-CoV-2 with multiple common
127 respiratory pathogens in infected patients. *Sci China Life Sci* 2020; 63,
128 <http://doi.org/10.1007/s11427-020-1668-5>.
- 129 8. **Touzard-Romo F, Tapé C, Lonks JR.** 2020. Co-infection with SARS-CoV-2 and
130 Human Metapneumovirus I *Med J (2013)*; Mar 19; 103(2):75-76.
- 131 9. **Fan BE, Lim KGE, Chong VCL, Chan SSW, Ong KH, Kuperan P.** 2020.
132 COVID-19 and *Mycoplasma pneumoniae* coinfection. *Am J Hematol*; Mar 15. doi:
133 10.1002/ajh.25785. [Epub ahead of print].
- 134 10. **Costa E, Rodríguez-Domínguez M, Clari MÁ, Giménez E, Galán JC, Navarro**
135 **D.** 2015. Comparison of the performance of 2 commercial multiplex PCR platforms for
136 detection of respiratory viruses in upper and lower tract respiratory specimens. *Diagn*
137 *Microbiol Infect Dis*; 82:40-43.
- 138 11. **Tanner H, Boxall E, Osman H.** 2012. Respiratory viral infections during the 2009-
139 2010 winter season in Central England, UK: incidence and patterns of multiple virus co-
140 infections *Eur J Clin Microbiol Infect Dis*; 31:3001-3006.

- 141 12. **To KKW, Chan KH, Ho J.** 2019. Respiratory virus infection among hospitalized
 142 adult patients with or without clinically apparent respiratory infection: a prospective
 143 cohort study. *Clin Microbiol Infect*;25:1539-1545.
- 144 13. **Winichakoon P, Chaiwarith R, Liwsrisakun C, Salee P, Goonna A, Limsukon**
 145 **A, Kaewpoowat Q.** 2020. Negative Nasopharyngeal and Oropharyngeal Swab Does
 146 Not Rule Out COVID-19. *J Clin Microbiol*; Feb 26. pii: JCM.00297-20. doi:
 147 10.1128/JCM.00297-20. [Epub ahead of print].
- 148 14. **Schultz-Cherry S.** 2015. Viral Interference: The Case of Influenza Viruses. *J Infect*
 149 *Dis* 212:1690-1691.
- 150 .

TABLE 1. Detection of respiratory pathogens by multiplexed PCR in the study patients				
Respiratory pathogens ^a	Patients			
	SARS CoV-2 positive (n=103) ^b	SARS CoV-2 negative clinical, laboratory and imaging compatible with Covid-19 (n=23) ^c	Respiratory infections with no suspicion of Covid-19 (n=48) ^d	Respiratory infections in season 2019 (n=50) ^e
One target	2	6	10	12
Adenovirus	0	0	1	0
Coronavirus HKU1	1	0	0	0
Coronavirus 229E	0	0	0	2

Coronavirus OC43	0	0	2	0
Coronavirus NL63	0	0	0	0
Human Bocavirus	0	0	0	0
Human Metapneumovirus	0	0	1	1
Influenza virus A	0	1	1	2
<i>Mycoplasma pneumoniae</i>	1	0	0	0
Parainfluenza virus 3	0	0	0	1
Respiratory Syncytial virus (A/B)	0	1	0	0
Rhinovirus-Enterovirus	0	4	5	6
Two targets	1	0	2	6
Adenovirus/Influenza virus A (H3)	0	-	0	2
Coronavirus 229E/Coronavirus NL63	0	-	0	1
Coronavirus 229E/Rhinovirus-Enterovirus	0	-	0	1
Human Metapneumovirus/Coronavirus 229E	0	-	2	0
Human Metapneumovirus/Parainfluenza virus 3	0	-	0	2
Influenza virus A (H1)/Respiratory syncytial virus A	1	-	0	0
Naso and oropharyngeal swabs were collected with flocked swabs in universal transport				

medium (Beckton Dickinson, Sparks, MD, USA, or Copan Diagnostics, Murrieta, CA, USA). Tracheal aspirates, sputa and bronchoalveolar lavage fluids were transported undiluted. Specimens were received at the laboratory within 30 min of collection and were conserved at 4 ° C until processed (within 6 hours). Nucleic acid extraction was performed using the Qiagen EZ-1 Viral extraction kit or the DSP virus Pathogen Minikit on the EZ1 or QiaSymphony Robot instruments (Qiagen, Valencia, CA, USA), respectively.

^aAs determined by the NxTAG® Respiratory Pathogen Panel (Luminex Corp, Austin, Tx, USA), which includes the following targets: Adenovirus, Influenza A, Influenza A (H1), Influenza A (H3), Influenza B, Parainfluenza virus 1-4, Coronavirus HKU1, NL63,229E, OC43, Respiratory Syncytial Virus A, Respiratory Syncytial Virus B, Human Metapneumovirus, Human Bocavirus, Rhinovirus-Enterovirus, *Chlamydomphila pneumoniae* and *Mycoplasma pneumoniae*.

^bSeveral commercially available assays were used for SARS CoV-19 detection, including the LightMix® Modular SARS and Wuhan CoV E-gene/LightMix® Modular Wuhan CoV RdRP-gene from TIB MOLBIOL GmHD, distributed by Roche Diagnostics (Pleasanton, CA, USA) on the Light Cycler 2.0 instrument, the SARS-COV-2 REALTIME PCR KIT from Vircell Diagnostics (Granada, Spain) or the REALQUALITY RQ-2019-nCoV from AB ANALITICA (Padua, Italy), both on the Applied Biosystems 7500 instrument. Detection of two SARS Cov-2 viral gene targets was considered a positive result. Respiratory specimens tested were the following: nasopharyngeal exudates (n=60), nasopharyngeal aspirates (n=21), oropharyngeal exudates (n=17), tracheal aspirates (n=3), and sputa (n=2).

^cRespiratory specimens tested were the following: nasopharyngeal aspirates (n=14), nasopharyngeal exudates (n=4), tracheal aspirates (n=3), sputum (n=1), and bronchoalveolar lavage fluid (n=1).

^dPatients in this group (31 males/17 females; median age, 61 years; range, 24-84 years) were screened for RP in respiratory specimens. In our center, as per protocol, onco-hematological patients with upper or lower respiratory tract infections and hospitalized patients with pneumonia of probable viral origin are routinely tested for RP. Respiratory specimens tested from these patients were the following: nasopharyngeal aspirates (n=18), nasopharyngeal exudates (n=9), tracheal aspirates (n=8), sputa (n=4), and bronchoalveolar

lavage fluids (n=9).

°Patients in this group (28 males/22 females; median age, 58 years; range, 19-78 years) were screened for RP in respiratory specimens as per protocol (as detailed above). Respiratory specimens tested were the following: nasopharyngeal aspirates (n=24), nasopharyngeal exudates (n=5), tracheal aspirates (n=8), sputa (n=3), and bronchoalveolar lavage fluids (n=10).

151

152

153

154

155

156

157

158

159

160

161

162